ARQT:NASDAQ, Arcutis Biotherapeutics, Inc.
ARQT stock overview
Arcutis Biotherapeutics, Inc. (ARQT:NASDAQ) closed at $26.36 on November 20, 2026,
down 2.98% on the day.
The stock trades 24.3% below its 52-week high of $34.80
and 36.6% above its 52-week low of $19.30.
Over the past year, it lost 10.6%.
Arcutis Biotherapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $26.36
- Day change
- -2.98%
- Volume
- 1,290,015
- Average volume
- 2,594,581
- Market cap
- 3B+
- 52-week range
- $19.30 – $34.80
- 50-day average
- $27.81
- 200-day average
- $25.41
Price action over the past year
In 252 trading sessions since November 20, 2025, ARQT closed higher on 125 days (50%).
Its best day was September 16, 2026 (+11.19%) and its worst was November 5, 2026 (-20.70%).
The stock moved 10% or more in a single session 6 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
ARQT news
-
Nov 14, 2026:
Arcutis Biotherapeutics (ARQT) Stock Looks Expensive Despite Its Huge Three Year Run
-
Nov 13, 2026:
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
-
Nov 13, 2026:
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
-
Nov 7, 2026:
Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ...
-
Nov 6, 2026:
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nov 6, 2026:
Arcutis Biotherapeutics (ARQT) Raised 2026 Sales Guidance, Is The Upside Already Priced In?
-
Nov 5, 2026:
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
-
Nov 5, 2026:
Arcutis Biotherapeutics, Inc. Q3 2026 Earnings Call Summary
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The company targets immune-mediated dermatological diseases and conditions, or immuno-dermatology.
Similar stocks
Find more stocks like ARQT with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.